Perseus Proteomics Inc. provided consolidated earnings guidance for the Fiscal Year Ending March 31, 2023. For the period, the company expects net sales to be JPY 77 million, operating loss to be JPY 703 million, loss to be JPY 854 million, basic loss per share to be JPY 72.62.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
344 JPY | -1.43% | +14.67% | -44.34% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.34% | 26.72M | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.36% | 15.36B | |
-8.82% | 11.95B | |
-15.40% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- 4882 Stock
- News Perseus Proteomics Inc.
- Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023